BNP Paribas Financial Markets Sells 19,513 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

BNP Paribas Financial Markets reduced its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 35.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 35,801 shares of the biopharmaceutical company’s stock after selling 19,513 shares during the quarter. BNP Paribas Financial Markets’ holdings in Ocular Therapeutix were worth $311,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Ocular Therapeutix by 7,098.7% in the third quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock valued at $3,779,000 after purchasing an additional 428,335 shares during the period. The Manufacturers Life Insurance Company increased its position in Ocular Therapeutix by 11.3% during the third quarter. The Manufacturers Life Insurance Company now owns 130,202 shares of the biopharmaceutical company’s stock worth $1,133,000 after acquiring an additional 13,238 shares during the period. Charles Schwab Investment Management Inc. increased its position in Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after acquiring an additional 660,080 shares during the period. Intech Investment Management LLC bought a new position in Ocular Therapeutix during the third quarter worth about $422,000. Finally, GSA Capital Partners LLP bought a new position in Ocular Therapeutix during the third quarter worth about $1,102,000. 59.21% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Jeffrey S. Heier sold 2,948 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now directly owns 269,059 shares of the company’s stock, valued at approximately $2,424,221.59. The trade was a 1.08 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on OCUL. Scotiabank began coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Ocular Therapeutix presently has an average rating of “Moderate Buy” and an average target price of $16.71.

Ocular Therapeutix Stock Performance

NASDAQ OCUL opened at $8.69 on Monday. The company has a fifty day simple moving average of $10.06 and a 200 day simple moving average of $8.52. Ocular Therapeutix, Inc. has a 12-month low of $3.24 and a 12-month high of $11.77. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The company has a market cap of $1.37 billion, a P/E ratio of -6.58 and a beta of 1.19.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.